Chronic-Pain Patients on Immediate-Release Tramadol Can Be Readily Switched to Once-Daily Extended-Release Formulation: Presented at ACCP
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Chronic-Pain Patients on Immediate-Release Tramadol Can Be Readily Switched to Once-Daily Extended-Release Formulation: Presented at ACCP

By Maria Bishop

BOSTON, MA -- September 19, 2006 -- Patients receiving various dosing regimens of the analgesic tramadol hydrochloride (HCl) immediate-release (IR) for moderate to moderately severe chronic pain can be readily switched to once-daily tramadol extended-release (ER), according to researchers speaking here at the American College of Clinical Pharmacology 35th Annual Meeting (ACCP).

Bindu P. Murthy, PharmD, Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, New Jersey, led a team of investigators in determining that patients taking tramadol IR (dosed at a lower amount every 6 hours) can be readily switched to the same equivalent daily dose across the full range of available strengths of tramadol ER (100 mg, 200 mg, and 300 mg).

The team used data from 2,248 plasma samples from 61 healthy men and women under fasting conditions (based on modeling data pooled from three phase I studies). The total clearance of drug after extravascular administration (CL/F) and apparent volume of distribution after extravascular administration (Vd/F) were the same for both ER and IR formulations, with simultaneous fit of pharmacokinetic data from both treatments. A strong correlation (0.67) was observed between CL/F and Vd/F.

Monte Carlo simulations also resulted in similar plasma tramadol concentrations for tramadol ER 200 mg once daily and tramadol IR 50 mg every 6 hours. Similar results were obtained for the Monte Carlo simulation that compared total doses of 100 mg or 300 mg between the 2 formulations.

Dr. Murthy's team undertook this study to determine how best to transition patients from tramadol IR to ER with optimal reduction of breakthrough pain and withdrawal symptoms.

They recommended that patients taking intermediate tramadol IR doses be transitioned to the next lower 100-mg tramadol ER increment (e.g., for a total daily dose of 225 to 275 mg tramadol IR, a 200-mg ER dose is suggested).

Tramadol is an analgesic agent with a mode of action that resembles that of narcotics, but with less potential for abuse and addiction.

[Presentation title: Dose Conversion of Immediate- to Extended-Release Tramadol Using a Population Pharmacokinetic Approach. Abstract 124]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities